Longitudinal analysis of the humoral response to Kaposi's sarcoma-associated herpesvirus after primary infection in children

Landon N. Olp, Veenu Minhas, Clement Gondwe, Lisa K. Poppe, A. Michelle Rogers, Chipepo Kankasa, John T West, Charles Wood

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent for Kaposi's sarcoma (KS)—one of the most common pediatric cancers in sub-Saharan Africa—however, the factors that lead to disease progression are not fully understood. HIV infection, immunosuppression, and high KSHV viral load increase the risk of developing KS, suggesting that the loss of an effective anti-KSHV immune response may be an important risk factor. However, very little is known about the KSHV-specific immune response prior to KS and less is known about the anti-KSHV immune response during the very early stages of infection. We therefore prospectively followed a cohort of 86 Zambian children for 2 years after primary KSHV seroconversion to characterize the humoral immune response during the early stages of KSHV infection. Plasma, peripheral blood mononuclear cells, and oral swabs were collected from patients every 3 months and analyzed for KSHV-specific antibodies and presence of viral DNA. We observed an approximately 40% KSHV seropositive rate among infected children at time points after primary seroconversion, indicating that seroreversion is common after primary KSHV infection. At the time of primary KSHV seroconversion HIV-infected ART-naïve children had a more robust KSHV antibody response compared to HIV-infected children taking ART and HIV-uninfected children. Conversely, the longitudinal anti-KSHV antibody response was highly variable and did not correlate with available clinical information, HIV/ART status, or presence of KSHV DNA. Collectively, our data suggest that there is limited impact by the variations in the humoral immune response in young children after infection. J. Med. Virol. 88:1973–1981, 2016.

Original languageEnglish (US)
Pages (from-to)1973-1981
Number of pages9
JournalJournal of Medical Virology
Volume88
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Human Herpesvirus 8
Infection
Kaposi's Sarcoma
Herpesviridae Infections
HIV
Humoral Immunity
Antibody Formation
HIV Seropositivity
Viral DNA
Viral Load
Immunosuppression
HIV Infections

Keywords

  • HIV
  • Zambia
  • human herpesvirus-8

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Longitudinal analysis of the humoral response to Kaposi's sarcoma-associated herpesvirus after primary infection in children. / Olp, Landon N.; Minhas, Veenu; Gondwe, Clement; Poppe, Lisa K.; Rogers, A. Michelle; Kankasa, Chipepo; West, John T; Wood, Charles.

In: Journal of Medical Virology, Vol. 88, No. 11, 01.11.2016, p. 1973-1981.

Research output: Contribution to journalArticle

Olp, Landon N. ; Minhas, Veenu ; Gondwe, Clement ; Poppe, Lisa K. ; Rogers, A. Michelle ; Kankasa, Chipepo ; West, John T ; Wood, Charles. / Longitudinal analysis of the humoral response to Kaposi's sarcoma-associated herpesvirus after primary infection in children. In: Journal of Medical Virology. 2016 ; Vol. 88, No. 11. pp. 1973-1981.
@article{8350da39387942b4abcc1bb969bba261,
title = "Longitudinal analysis of the humoral response to Kaposi's sarcoma-associated herpesvirus after primary infection in children",
abstract = "Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent for Kaposi's sarcoma (KS)—one of the most common pediatric cancers in sub-Saharan Africa—however, the factors that lead to disease progression are not fully understood. HIV infection, immunosuppression, and high KSHV viral load increase the risk of developing KS, suggesting that the loss of an effective anti-KSHV immune response may be an important risk factor. However, very little is known about the KSHV-specific immune response prior to KS and less is known about the anti-KSHV immune response during the very early stages of infection. We therefore prospectively followed a cohort of 86 Zambian children for 2 years after primary KSHV seroconversion to characterize the humoral immune response during the early stages of KSHV infection. Plasma, peripheral blood mononuclear cells, and oral swabs were collected from patients every 3 months and analyzed for KSHV-specific antibodies and presence of viral DNA. We observed an approximately 40{\%} KSHV seropositive rate among infected children at time points after primary seroconversion, indicating that seroreversion is common after primary KSHV infection. At the time of primary KSHV seroconversion HIV-infected ART-na{\"i}ve children had a more robust KSHV antibody response compared to HIV-infected children taking ART and HIV-uninfected children. Conversely, the longitudinal anti-KSHV antibody response was highly variable and did not correlate with available clinical information, HIV/ART status, or presence of KSHV DNA. Collectively, our data suggest that there is limited impact by the variations in the humoral immune response in young children after infection. J. Med. Virol. 88:1973–1981, 2016.",
keywords = "HIV, Zambia, human herpesvirus-8",
author = "Olp, {Landon N.} and Veenu Minhas and Clement Gondwe and Poppe, {Lisa K.} and Rogers, {A. Michelle} and Chipepo Kankasa and West, {John T} and Charles Wood",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/jmv.24546",
language = "English (US)",
volume = "88",
pages = "1973--1981",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Longitudinal analysis of the humoral response to Kaposi's sarcoma-associated herpesvirus after primary infection in children

AU - Olp, Landon N.

AU - Minhas, Veenu

AU - Gondwe, Clement

AU - Poppe, Lisa K.

AU - Rogers, A. Michelle

AU - Kankasa, Chipepo

AU - West, John T

AU - Wood, Charles

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent for Kaposi's sarcoma (KS)—one of the most common pediatric cancers in sub-Saharan Africa—however, the factors that lead to disease progression are not fully understood. HIV infection, immunosuppression, and high KSHV viral load increase the risk of developing KS, suggesting that the loss of an effective anti-KSHV immune response may be an important risk factor. However, very little is known about the KSHV-specific immune response prior to KS and less is known about the anti-KSHV immune response during the very early stages of infection. We therefore prospectively followed a cohort of 86 Zambian children for 2 years after primary KSHV seroconversion to characterize the humoral immune response during the early stages of KSHV infection. Plasma, peripheral blood mononuclear cells, and oral swabs were collected from patients every 3 months and analyzed for KSHV-specific antibodies and presence of viral DNA. We observed an approximately 40% KSHV seropositive rate among infected children at time points after primary seroconversion, indicating that seroreversion is common after primary KSHV infection. At the time of primary KSHV seroconversion HIV-infected ART-naïve children had a more robust KSHV antibody response compared to HIV-infected children taking ART and HIV-uninfected children. Conversely, the longitudinal anti-KSHV antibody response was highly variable and did not correlate with available clinical information, HIV/ART status, or presence of KSHV DNA. Collectively, our data suggest that there is limited impact by the variations in the humoral immune response in young children after infection. J. Med. Virol. 88:1973–1981, 2016.

AB - Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent for Kaposi's sarcoma (KS)—one of the most common pediatric cancers in sub-Saharan Africa—however, the factors that lead to disease progression are not fully understood. HIV infection, immunosuppression, and high KSHV viral load increase the risk of developing KS, suggesting that the loss of an effective anti-KSHV immune response may be an important risk factor. However, very little is known about the KSHV-specific immune response prior to KS and less is known about the anti-KSHV immune response during the very early stages of infection. We therefore prospectively followed a cohort of 86 Zambian children for 2 years after primary KSHV seroconversion to characterize the humoral immune response during the early stages of KSHV infection. Plasma, peripheral blood mononuclear cells, and oral swabs were collected from patients every 3 months and analyzed for KSHV-specific antibodies and presence of viral DNA. We observed an approximately 40% KSHV seropositive rate among infected children at time points after primary seroconversion, indicating that seroreversion is common after primary KSHV infection. At the time of primary KSHV seroconversion HIV-infected ART-naïve children had a more robust KSHV antibody response compared to HIV-infected children taking ART and HIV-uninfected children. Conversely, the longitudinal anti-KSHV antibody response was highly variable and did not correlate with available clinical information, HIV/ART status, or presence of KSHV DNA. Collectively, our data suggest that there is limited impact by the variations in the humoral immune response in young children after infection. J. Med. Virol. 88:1973–1981, 2016.

KW - HIV

KW - Zambia

KW - human herpesvirus-8

UR - http://www.scopus.com/inward/record.url?scp=84984856770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984856770&partnerID=8YFLogxK

U2 - 10.1002/jmv.24546

DO - 10.1002/jmv.24546

M3 - Article

C2 - 27062052

AN - SCOPUS:84984856770

VL - 88

SP - 1973

EP - 1981

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 11

ER -